

CURRICULUM VITAE**INFORMAZIONI PERSONALI**

COGNOME E NOME

VENERONI SILVIA IRENE

DATA DI NASCITA

08 GIUGNO 1957

AMMINISTRAZIONE

FONDAZIONE IRCCS – ISTITUTO NAZIONALE DEI TUMORI

INCARICO E STRUTTURA

DIRIGENTE I LIVELLO- STRUTTURA COMPLESSA SPERIMENTALE

NUMERO TELEFONICO UFFICIO

02-2390-2822

FAX UFFICIO

02-2390-2692

E-MAIL ISTITUZIONALE

silvia.veneroni@istitutotumori.mi.it

**TITOLI DI STUDIO E PROFESSIONALI ED
ESPERIENZE
LAVORATIVE**

TITOLO DI STUDIO

BIOLOGO

ALTRI TITOLI DI STUDIO E
PROFESSIONALI

ABILITAZIONE ALLA PROFESSIONE DI BIOLOGO

ESPERIENZE PROFESSIONALI

COORDINAMENTO E GESTIONE DELLA BANCA DI TESSUTI CRIOCONSERVATI E DELLA BANCA DEL SANGUE ISTITUZIONALI; GESTIONE E MANTENIMENTO DI DATABASE CONTENENTI INFORMAZIONI BIOLOGICHE, CLINICO-PATOLOGICHE E DI FOLLOW-UP DI PAZIENTI PORTATRICI DI DIVERSE NEOPLASIE. RICERCA E SPERIMENTAZIONE MEDIANTE METODOLOGIE DI IMMUNOISTOCHEMICA, UTILIZZANDO BIOMARCATORI DI POTENZIALE RILEVANZA CLINICA PER LA DEFINIZIONE DI DIVERSI PARAMETRI BIOLOGICI IN TUMORI UMANI. ESPERIENZA SEMESTRALE PRESSO LAWRENCE LIVERMORE NATIONAL LABORATORY (CALIFORNIA-USA) PER ANALISI BIPARAMETRICHE E PERTURBAZIONI DEL CICLO CELLULARE IN TUMORI SPERIMENTALI MEDIANTE CITOMETRIA A FLUSSO.

CAPACITÀ LINGUISTICHE

LINGUA	LIVELLO PARLATO	LIVELLO SCRITTO
INGLESE	FLUENTE	FLUENTE

CAPACITÀ NELL'USO DELLE TECNOLOGIE

CONOSCENZA E UTILIZZO DI MICROSOFT OFFICE, PROGRAMMI SAS E GESTIONE DI DATABASE

ALTRO

PARTECIPAZIONE E RELAZIONI A CONVEGNI, SEMINARI, PUBBLICAZIONI, COLLABORAZIONI A RIVISTE, ECC., ED OGNI ALTRA INFORMAZIONE CHE SI RITENGA DI DOVER PUBBLICARE.

PARTECIPAZIONE A CONVEGNI E PUPPLICAZIONI (VEDI ALLEGATO)

Pubblicazioni
Dott.ssa Silvia VENERONI

1. G. Del Bino, R. Silvestrini, A. Costa, **S. Veneroni**, R. Giardini. Morphological and clinical significance of cell kinetics in non-Hodgkin's lymphomas. *Bas. Appl. Histochem.*, 30: 197-202, 1986.
2. Costa, G. Del Bino, G-. Mazzini, **S. Veneroni**, R. Silvestrini. Comparative analysis of different cell kinetics variables in non-Hodgkin's lymphomas. *Progress in Flow Cytometry. Reports from FACS User Conference. Becton Dickinson*, pp. 187-194, 1986.
3. **S. Veneroni**, A. Costa, R. Motta, R. Giardini, F. Rilke, R. Silvestrini. Comparative analysis of ³H-thymidine labeling index and monoclonal antibody Ki-67 in non-Hodgkin's lymphomas. *Hematological Oncology*, 6: 21-28, 1988.
4. R. Silvestrini, A. Costa, **S. Veneroni**, G. Del Bino, P. Persici. Comparative analysis of different approaches to investigate cell kinetics. *Cell Tissue Kinetics*. 21: 123-131, 1988.
5. R. Silvestrini, A. Costa, R. Molinari, **S. Veneroni**. Studio dell'attività proliferativa delle popolazioni cellulari e sue possibili applicazioni cliniche. In: *I Tumori della Testa e Collo. U. Veronesi, R. Molinari, A. Banfi, A. Santoro (eds.) Casa Editrice Ambrosiana, Milano*, pp. 37-40, 1990.
6. R. Molinari, A. Costa, **S. Veneroni**, F. Mattavelli, B. Salvatori, R. Silvestrini. Cell kinetics and response to primary intra-arterial chemotherapy in patients with advanced oral cavity tumors. *J. Oral Pathol. & Medicine*, 20: 32-36, 1991.
7. R. Silvestrini, G. Muscolino, A. Costa, C. Lequaglie, **S. Veneroni**, G. Mezzanotte, G. Ravasi. Could cell kinetics be a predictor of prognosis in non-small cell lung cancer? *Lung Cancer*, 7: 165-170, 1991.
8. A. Costa, R. Silvestrini, R. Giardini, G. Messina-Gabrielli, P. Boracchi, **S. Veneroni**. Contribution of ³H-thymidine labeling index and flow cytometric S-phase in predicting survival of patients with non-Hodgkin's lymphoma. *Br. J. Cancer*, 66: 680-684, 1992.
9. R. Silvestrini, **S. Veneroni**, E. Benini, G. Di Fronzo, M.G. Daidone. P53 and cathepsin D are independent of established prognostic factors in breast cancer. *Int. J. Oncol.*, 1: 507-512, 1992.
10. **S. Veneroni**, M.G. Daidone, G. Di Fronzo, V. Cappelletti, D. Amadori, A. Riccobon, A. Paradiso, M. Correale, R. Silvestrini. Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. *Br. Cancer Res. Treat.*, 26: 7-13, 1993.

11. R. Silvestrini, E. Benini, M.G. Daidone, **S. Veneroni**, P. Boracchi, V. Cappelletti, G. Di Fronzo, U. Veronesi. P53 as an independent prognostic marker in lymph node-negative breast cancer patients. *J. Natl. Cancer Inst.*, 85: 965-970, 1993.
12. E. Benini, A. Costa, G. Pizzocaro, B. Campo, A. Milani, T. Torelli, **S. Veneroni**, G. Ordesi, S. Pilotti, R. Silvestrini. Biological markers in transurethral biopsies from bladder cancer: preliminary results. *Int. J. Oncol.*, 3: 817-821, 1993.
13. R. Silvestrini, **S. Veneroni**, M.G. Daidone, E. Benini, P. Boracchi, M. Mezzetti, G. Di Fronzo, U. Veronesi. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. *J. Natl. Cancer Inst.*, 86: 499-504, 1994.
14. **S. Veneroni**, N. Zaffaroni, M.G. Daidone, E. Benini, R. Villa, R. Silvestrini. Expression of p-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. *Eur. J. Cancer*, 30A: 1002-1007, 1994.
15. L. Orlandi, N. Zaffaroni, D. Gornati, **S. Veneroni**, R. Silvestrini. Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer. *Anticancer Res.*, 14: 1161-1164, 1994.
16. R. Silvestrini, E. Benini, A. Luisi, **S. Veneroni**, B. Valentini, M.G. Daidone. Biology of breast cancer in elderly women. *Mastology breast diseases A.S.S. Figueira FO et al, editors: 255-257, 1995.*
17. M.G. Daidone, R. Silvestrini, A. Luisi, M. Mastore, E. Benini, **S. Veneroni**, C. Brambilla, L. Ferrari, M. Greco, S. Andreola, U. Veronesi. Changes in biological markers after primary chemotherapy for breast cancers. *Int. J. Cancer*, 61: 301-305, 1995.
18. R. Silvestrini, E. Benini, **S. Veneroni**, M.G. Daidone, G. Tomasic, P. Squicciarini, B. Salvadori. P53 and Bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. *J. Clin. Oncol.*, 14: 1604-1610, 1996.
19. M.G. Daidone, U. Ricardi, **S. Veneroni**, A. Faranda, E. Benini, A. Urgesi, G.L. Sannazzari, R. Silvestrini. Biological predictors of response to radiotherapy in cervical carcinomas. *Int. J. Oncol.*, 10: 41-46, 1997.
20. R. Silvestrini, **S. Veneroni**, E. Benini, M.G. Daidone, A. Luisi, M. Leutner, A. Maucione, R. Kenda, R. Zucali, U. Veronesi. Expression of p53, GST- π and bcl-2 and benefit from adjuvant radiotherapy in breast cancer. *J. Natl. Cancer Inst.*, 89: 639-645, 1997.
21. R. Villa, D. Gornati, N. Zaffaroni, **S. Veneroni**, P. Bidoli, A. Severini.

Comparative *in vitro* sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents. *Anticancer Res.*, 17: 961-968, 1997.

22. R. Silvestrini, M.G. Daidone, **S. Veneroni**, E. Benini, G. Scarfone, F. Zanaboni, A. Villa, M. Presti, S. Danese, G. Bolis. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. *Cancer* 82: 159-67, 1998.
23. R. Silvestrini, A. Costa, C. Lequaglie, C. Mochen, **S. Veneroni**, M. Leutner, G. Ravasi. Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. *Virchows Arch.* 432: 441-444, 1998.
24. **S. Veneroni**, R. Silvestrini, A. Costa, P. Salvatori, A. Faranda, R. Molinari. Biological Indicators of survival in patients treated by surgery for squamous cell carcinoma of the oral cavity and oropharynx. *Eur. J. Cancer*, 33: 408-413, 1997.
25. A. Costa, L. Licitra, **S. Veneroni**, M.G. Daidone, C. Grandi, R. Cavina, R. Molinari, R. Silvestrini. Biological markers as indicators of Pathological response to primary chemotherapy in oral cavity cancers. *Int. J. Cancer (Pred. Oncol.)*, 79: 619-623, 1998.
26. M.G. Daidone, **S. Veneroni**, E. Benini, G. Tomasic, D. Coradini, M. Mastore, C. Brambilla, L. Ferrari, R. Silvestrini. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. *Int J Cancer (pred Oncol)* 84:580-586, 1999.
27. M.G. Daidone, A. Luisi, **S. Veneroni**, E. Benini, R. Silvestrini. Clinical studies of bcl-2 and treatment benefit in breast cancer patients. *Endocrine-Related Cancer*, 6: 61-68, 1999.
28. M.G. Daidone, **S. Veneroni**, E. Benini, G. Tomasic, D. Coradini, C. Brambilla, L. Ferrari, R. Silvestrini. Biological markers and changes induced in their profiles following primary chemotherapy: relevance for short- and long-term clinical outcome. *Biol. Markers and Primary Chemotherapy (ESO)*, 4: 53-72, 1999.
29. M.G. Daidone, A. Luisi, G. Martelli, E. Benini, **S. Veneroni**, G. Tomasic, G. De Palo, R. Silvestrini. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women. *Br. J. Cancer*, 82: 270-277, 2000.
30. D. Laccabue, M. Tortoreto, **S. Veneroni**, P. Perego, E. Scanziani, M. Zucchetti, M. Zaffaroni, M. D'Incalci, E. Bombardelli, F. Zunino, G. Pratesi. A novel taxane active against an orthotopically growing human glioma xenograft. *Cancer*, 12: 3085-3092, 2001.
31. M.G. Daidone, **S. Veneroni**, V. Cappelletti, P. Radice, M.A. Pierotti, M. Younes. Estrogen receptor-beta expression in hereditary breast cancer. *J. Clin. Oncol.*, 20: 3752-3753, 2002.

32. D. Coradini, **S. Veneroni**, C. Pellizzaro, L. Ventura, M.G. Daidone. Infiltrating ductal and lobular breast carcinomas are characterized by different interrelationships among markers related to angiogenesis and hormone dependence. *Br. J. Cancer* 87:1105-1111, 2002.
33. M.G. Daidone, **S. Veneroni**. Indici di proliferazione cellulare: rilevanza clinica nel carcinoma della mammella. *Ligand Assay* 7: 92-102, 2002.
34. M.G. Daidone, D. Coradini, G. Martelli, **S. Veneroni**. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. *Critical Reviews in Oncology/Hematology*, 45: 313-325, 2003.
35. V. Cappelletti, **S. Veneroni**, D. Coradini, S. Oriana, G. Tomasic, M. Younes, M.G. Daidone. Tamoxifen may be an effective treatment for BRCA1-Related breast cancer irrespective of estrogen receptor status. *J. Ntl. Cancer Institute* 95: 629-630 , 2003.
36. D. Coradini, E. Biganzoli, C. Pellizzaro, **S. Veneroni**, S. Oriana, F. Ambrogi, R. Erdas, P. Boracchi, M.G. Daidone, E. Marubini. Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen. *Br.J. Cancer* 89: 268-270, 2003.
37. D. Coradini, **S. Veneroni**, C. Pellizzaro, M.G. Daidone. Fluctuation of intratumor biological variables as a function of menstrual timing of surgery in breast cancer from premenopausal patients. *Ann. of Oncol.* 14: 962-964, 2003.
38. M. De Cesare, G. Pratesi, **S. Veneroni**, R. Bergottini, F. Zunino. Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. *Clin Cancer Res.* 10: 7357-7364, 2004
39. M.G. Daidone, R. Silvestrini, A. Costa, D. Coradini, G. Martelli, **S. Veneroni**. In: “ *Comprehensive Geriatric Oncology*” – second editing- edited by L. Balducci, G. H. Lyman, W. B. Ershler, M. Exremann. Taylor and Francis 2004: 171-179.
40. J. F. Reid, L. Lusa, L. De Cecco, D. Coradini, **S. Veneroni**, M.G. Daidone, M. Gariboldi, M. Pierotti. Predictive models using microarray data for breast cancer clinical treatment outcome. *J Ntl Cancer Institute* 97(12): 927-930, 2005.
41. P. Gandellini, M. Folini, N. Longoni, M. Pennati, M. Binda, M. Colecchia, R. Salvioni, R. Supino, R. Moretti, P. Limonta, R. Valdagni, M.G. Daidone, and N. Zaffaroni. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase C ϵ . *Cancer Res* 69: (6) march 15, 2009
(in acknowledgments: we thank **Drs S. Veneroni** et al. for skilled technical assistance)
42. L. De Cecco, V. Musella, **S. Veneroni**, V. Cappelletti, I. Bongarzone, M. Callari, B. Valeri, M. Pierotti, and M.G. Daidone. Impact of biospecimens handling on biomarker research in breast cancer. *BMC Cancer* 9: 409, 2009

43. M. Folini, P. Gandellini, N. Longoni, M. Callari, M. Pennati, M. Colecchia, R. Supino **S. Veneroni**, R. Salvioni, R. Valdagni, M.G. Daidone, and N. Zaffaroni. miR-21: an oncomir on strike in prostate cancer. *Mol Cancer* Jan 21; 9-12, 2010
44. W. Feng, R. Orlandi, N. Zhao, M.L. Carcangiu, E. Tagliabue, J. Xu, R.C. Bast Jr, Y. Yu. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. *BMC Cancer* 10:378; 1-10, 2010
(in acknowledgments: we thank **Silvia Veneroni** for sample collection)
45. M. Callari, V. Cappelletti, L. De Cecco, D. Coradini, P. Miodini, **S. Veneroni**, M. Gariboldi, M. Pierotti, and M.G. Daidone. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. *Breast Cancer res Treat* 127 (3): 601-610, 2011
46. E. Sini, M. Torresani, **S. Veneroni**. Information and communication technologies (ICTs) for biobanking and oncology research. *Healthinf-BIOSTEC* Jan 2011
47. **S. Veneroni**, M.G. Daidone, M. Milione, M. Barisella, M. Torresani, E. Sini and M. Pierotti. Human tissue bank facility of the Fondazione IRCCS Istituto Nazionale Tumori (INT) of Milan: the tissue issue and beyond. *Biopreservation and Biobanking* 9(3): 289-313, 2011
48. R. Silvestrini, G. Martelli, R. Miceli, R. Agresti, **S. Veneroni** and M.G. Daidone. Cell proliferation of the primary tumor predicts ipsilateral axillary node relapse in elderly breast cancer patients (in press *Int J Biol Markers*, 2012)
49. S. Picelli, J L. Bermejo, J. Chang-Claude, M. Hoffmeister, C. Fernandez-Rozadilla, A. Carracedo, A. Castells, S. Castellví-Bel, The EPICOLON Consortium, A. Naccarati, B. Pardini, L. Vodickova, H. Muller, B.A. Talseth-Palmer, G. Stibbard, P. Peterlongo, C. Nici, **S. Veneroni**, L. Li, A. Tenesa, T. van Wezel, S. M. Farrington, I. Tomlinson, V. Moreno, J. Wijnen, M. Dunlop, P. Radice, R. J. Scott, P. Vodicka, C. Ruiz-Ponte, H. Brenner, S. Buch, A. Lindblom. Shrinkage of association signals with increasing sample size illustrated by a meta-analysis of six polymorphisms and colorectal cancer susceptibility (submitted to *Cancer Epidemiology Biomarkers and prevention*, 2012)

Partecipazione a Congressi
Dott.ssa Silvia VENERONI

1. A. Costa, R. Silvestrini, R. Molinari, P. Salvadori, **S. Veneroni**, R. Motta. Cell kinetics to predict biologic aggressivity and radioresponsivity in head and neck cancers. 9th CKS Meeting. Denver 5-9 March 1985.
2. G. Del Bino, R. Silvestrini, A. Costa, **S. Veneroni**, R. Giardini. Rilevanza prognostica dell'attività proliferativa nei linfomi non-Hodgkin. XX Congresso della Società Italiana di Istochimica. 30-31 Maggio 1985, Milano.
3. A. Costa, G. Del Bino, G. Mazzini, **S. Veneroni**, R. Silvestrini. Comparative analysis of different cell kinetic variables in non-Hodgkin lymphomas. FACS USERS Meeting 24-26 September 1985, Bologna.
4. **S. Veneroni**, A. Costa, G. Del Bino, S. Canova, R. Silvestrini. Confronto di diverse metodiche per la valutazione della frazione di cellule proliferanti nei linfomi non-Hodgkin. Terza Riunione Nazionale di Oncologia Sperimentale e Clinica. 18-20 Novembre 1985, Milano.
5. A. Costa, R. Silvestrini, G. Mazzini, **S. Veneroni**, G. Del Bino. Different cell kinetics approaches to determine the S-phase fraction in non-Hodgkin lymphomas. 10th CKS Meeting. 19-21 March 1986, Santa Fe, New Mexico.
6. A. Costa, G. Mazzini, **S. Veneroni**, G. Del Bino, R. Silvestrini. Determination of cell proliferation in human non-Hodgkin lymphomas by different biologic and technical approaches. 20-26 April 1986, Schloss Elmau, FRG.
7. A. Costa, G. Del Bino, G. Mazzini, **S. Veneroni**, and R. Silvestrini. Simple procedure for DNA pattern analysis. International Symposium on Breast Cancer. 1-4 January 1987. New Delhi, India.
8. **S. Veneroni**, A. Costa, S. Canova, R. Silvestrini. Cell proliferation of non-Hodgkin lymphomas as evaluated by 3H-thymidine labeling index and monoclonal antibody Ki-67. VIII AICC Meeting (ETCS - IB) Molecular Cytogenetics. 10 March 1987, Milano.
9. G. Del Bino, **S. Veneroni**, F. Lampariello, A. Costa, M.R. Zucconi, R. Silvestrini. Nuclear DNA content in human breast cancer. VIII AICC Meeting (ETCS - IB) Molecular Cytogenetics. 10 March 1987, Milano.
10. R. Silvestrini, A. Costa, M.G. Daidone, **S. Veneroni**, E. Grignolio. Clinical relevance of cell kinetics of primary and metastatic lesions in human tumors. 11th CKS Meeting. 26-28 March 1987, Vancouver, Canada.

11. **S. Veneroni**, A. Costa, R. Silvestrini. Comparative analysis of the 3H-thymidine labeling index and Ki-67 positive cells in non-Hodgkin lymphomas. 11th CKS Meeting. 26-28 March 1987, Vancouver, Canada.
12. R. Silvestrini, A. Costa, **S. Veneroni**, G. Del Bino. Clinical perspectives of cell kinetics in non-Hodgkin's lymphomas. 15th ESGCP Meeting. 16-20 September 1987. Sudvolden, Norway.
13. **S. Veneroni**, A. Costa, G. Del Bino, L. Ventura and R. Silvestrini. Perspectives of different methodologies to evaluate cell proliferating fraction in non-Hodgkin's lymphomas. 15th ESGCP Meeting. 16-20 September 1987. Sudvolden, Norway.
14. R. Silvestrini, A. Costa, **S. Veneroni**, G. Del Bino. Prospettive cliniche della cinetica cellulare nei linfomi non-Hodgkin. Incontro di aggiornamento su: Le Colture Cellulari: Attuali Prospettive di Applicazione Clinica. 27-28 Novembre 1987. Bologna.
15. **S. Veneroni**, R. Silvestrini, P. Salvatori, R. Molinari. Cell kinetics and response to chemotherapy of patients with advanced oral cavity tumors. 12th CKS Meeting. 23-26 March 1988. Omaha, U.S.A.
16. A. Costa, R. Silvestrini, G. Bonadonna, P. Valagussa, L. Verderio, **S. Veneroni**, L. Ferrari. Prognostic relevance of cell kinetics in non-Hodgkin's lymphomas. 24th ASCO Meeting. 22-24 May 1988. New Orleans, U.S.A.
17. G. Del Bino, M.R. Zucconi, **S. Veneroni**, A. Costa, G. Marchese, C. Selvi, R. Silvestrini. DNA ploidy in primary human tumors and metastatic lesions. 5th International Symposium on Morphological Diagnosis. 14-17 Settembre 1988. Ancona.
18. A. Costa, R. Silvestrini, **S. Veneroni**, M. Ponz de Leon, L. Bombelli. 3H-TdR LI in primary and metastatic colorectal cancer: clinical implications. 16th ESGCP Meeting. 3-6 May 1989, Milano.
19. A. Scalmati, R. Silvestrini, **S. Veneroni**, R. Giardini, F. Rilke. Cell proliferation kinetics and DNA ploidy in cancer of the large bowel. 16 ESGCP Meeting. 3-6 May 1989, Milano.
20. A. Costa, R. Silvestrini, **S. Veneroni**, R. Giardini, F. Rilke. Cell kinetics and ploidy of human non-Hodgkin's lymphoma. First Conference of the European Society for Analytical Cellular Pathology. 12-17 November 1989. Schloss Elmau, Fed. Rep. of Germany.
21. **S. Veneroni**, R. Silvestrini, A. Costa, R. Giardini, R. Motta. Cell kinetics and ploidy as predictors of tumor aggressiveness in non-Hodgkin's lymphomas. 2nd FACS User's Meeting Advances in Cytometry "Cytometry and Monoclonal Antibodies: Research and Clinical Applications". 29-31 Marzo 1990. Bologna.

22. **S. Veneroni**, R. Silvestrini, A. Costa, C. Le Quaglie. 3H-TdR LI as an indicator of progression in non-small cell lung (NSCL) cancer. 17th ESGCP Meeting. 13-15 September 1990. Helsinki.
23. **S. Veneroni**, M.G. Daidone, R. Silvestrini, E. Benini, L. Arboit. Relazione fra attività proliferativa determinata con 3H-TdR LI e Ki67 nel carcinoma mammario. I Congresso Nazionale S.I.C.C.A.B.. 25-27 Ottobre 1990. Modena.
24. **S. Veneroni**, E. Benini, A. Faranda, R. Silvestrini. Comparison of different cell kinetic variables in systemic and solid human tumors. 22-24 March, 1991. Kiawah island, South Carolina, U.S.A.
25. **S. Veneroni**, E. Benini, L. Arboit, M.G. Daidone, R. Erdas, R. Silvestrini. Expression of markers associated to proliferation and invasiveness in breast cancer. The 3rd Joint Meeting of the Cell Kinetics Society and the International Cell Cycle Society. 26-29 March, 1992. New Orleans, U.S.A.
26. E. Benini, R. Silvestrini, **S. Veneroni**, M.G. Daidone, W. Grigioni, A. D'Errico. Expression of markers associated to the extracellular matrix (ECM) and cell proliferation in breast cancer. 18th Meeting of the European Study Group for Cell Proliferation. 6-9 May 1992. Budapest, Hungary.
27. **S. Veneroni**, M.G. Daidone, S. Canova, R. Silvestrini. Espressione di bcl-2 nei carcinomi mammari in fase iniziale: correlazioni di base e prognostiche. II° Congresso Nazionale S.I.C.C.A.B. 25-26 Settembre 1992. Pisa.
28. M.G. Daidone, E. Benini, **S. Veneroni**, G. Di Fronzo, R. Silvestrini. P53 expression is an independent prognostic marker in node-negative breast cancer (N-BC). ASCO Annual Meeting. 16-18 May 1993. Orlando, U.S.A.
29. M.G. Daidone, **S. Veneroni**, E. Benini, R. Silvestrini. Expression of bcl-2 provides prognostic information in node-negative breast cancers (n-BC). AACR Meeting 19-22 May 1993. Orlando, U.S.A.
30. M.G. Daidone, R. Silvestrini, E. Benini, **S. Veneroni**, A. Luisi. Variation of biological markers in breast cancer after primary chemotherapy. 19th ESGCP Meeting. 5-9 October 1993. Brugges. Belgium.
31. **S. Veneroni**, R. Silvestrini, E. Benini, M.G. Daidone. Proliferation-related markers in breast cancer prognosis. 19th ESGCP Meeting. 5-9 October 1993. Brugges. Belgium.
32. E. Benini, **S. Veneroni**, T. Torelli, A. Milani, A. Costa, B. Campo, G. Pizzocaro, R. Silvestrini. Caratterizzazione biologica nel carcinoma a cellule di transizione della vescica. 3° Congresso Nazionale Società Italiana di Urologia Oncologica. 1-3 Dicembre 1993. Milano.

33. **S. Veneroni**, A. Costa, P. Salvatori, R. Molinari, R. Silvestrini. Prognostic role of cell proliferation to monitor radiosensitivity in oral cavity cancer patients. CKS Meeting. 24-27 March 1994. Louisville, Kentucky. U.S.A.
34. **S. Veneroni**, A. Costa, A. Faranda, P. Salvatori, R. Silvestrini. Potential of a biological characterization to monitor radiosensitivity in oral cavity cancer. III Congresso Nazionale S.I.C.C.A.B. Forlì, 22-24 Settembre 1994.
35. P. Salvatori, A. Costa, **S. Veneroni**, A. Faranda, R. Molinari and R. Silvestrini. S-phase cell fraction, p53 and bcl-2, prognostic indicators in advanced oral cavity cancer. Fourth Research Workshop on the Biology, Prevention and Treatment of Head and Neck Cancer. September 8-11, 1994. Hyatt Regency Crystal City, Arlington, Virginia. U.S.A.
36. M.G. Daidone, R. Silvestrini, E. Benini, **S. Veneroni**, G. Bolis, U. Ricardi. Modulation of proliferation-related markers following neoadjuvant treatments in cervical cancers. ESGCP Meeting 30 May - 3 June 1995. London.
37. A. Luisi, R. Silvestrini, M.G. Daidone, E. Benini, **S. Veneroni**, P. Boracchi. Validation process for prognostic markers: the breast cancer model. IV Congresso Nazionale S.I.C.C.A.B. Bari, 6-8 Giugno 1996.
38. **S. Veneroni**, P. Salvatori, A. Costa, A. Faranda, R. Molinari, R. Silvestrini. Prognostic relevance of biological markers in oral cavity and oropharynx squamous cell carcinomas. IV Congresso Nazionale S.I.C.C.A.B. Bari, 6-8 Giugno 1996.
39. R. Silvestrini, M.G. Daidone, E. Benini, **S. Veneroni**, A. Luisi, P. Boracchi. Validation process for proliferation-related prognostic markers in node-negative breast cancer. 21st Meeting of the International Association for Breast Cancer Research. 3-5 July 1996. Paris.
40. **S. Veneroni**, P. Salvadori, A. Costa, A. Faranda, R. Molinari, R. Silvestrini. Proliferation-related markers as predictors of prognosis in oral cavity and oropharynx squamous cell carcinomas. 19-22 September 1996. Uppsala.
41. A. Costa, **S. Veneroni**, C. Mochen, A. Azzarelli, R. Silvestrini. Proliferazione cellulare e ploidia nella prognosi dei sarcomi delle parti molli dell'adulto. II Riunione Gruppo di Studio S.I.C., Indicatori biologici in oncologia. 29 Settembre 1997. Bertinoro.
42. M.G. Daidone, A. Luisi, E. Benini, **S. Veneroni**, R. Silvestrini. Methodologies for translational research in oncology, with special reference to proliferation markers. Translational Research in Oncology: Prognosis and Prediction of Treatment Response. 22nd Meeting of the European Study Group for Cell Proliferation and

5th National Congress of the Italian Society for Basic and Applied Cell Kinetics. 6-9 May 1998, Rimini.

43. **S. Veneroni**, M.G. Daidone, A. Luisi, R. Silvestrini. Bcl-2 and bax as predictors of apoptosis and radiation response in breast cancer. Translational Research in Oncology: Prognosis and Prediction of Treatment Response. 22nd Meeting of the European Study Group for Cell Proliferation and 5th National Congress of the Italian Society for Basic and Applied Cell Kinetics. 6-9 May 1998, Rimini.
44. A. Costa, E. Benini, G. Di Mauro, **S. Veneroni**, R. Silvestrini. Proliferation-related markers: relevance for clinical outcome of melanoma patients. Translational Research in Oncology: Prognosis and Prediction of Treatment Response. 22nd Meeting of the European Study Group for Cell Proliferation and 5th National Congress of the Italian Society for Basic and Applied Cell Kinetics. 6-9 May 1998, Rimini.
45. M.G. Daidone, **S. Veneroni**, E. Benini, A. Luisi, G. Martelli, G. De Palo, R. Silvestrini. Postmenopausal women with lymph node-positive (N+), estrogen receptor positive (ER+) breast cancer given adjuvant tamoxifen: role of p27kip1, cyclin E and other proliferation-related markers in identifying subsets at different prognosis. AACR Annual Meeting. 10-14 April, 1999. Philadelphia.
46. **S. Veneroni**, E. Benini, L. Dressino, M.G. Daidone. P27kip1 in human breast cancer: role as a predictor of prognosis and response to hormonal treatment. European Study Group for Cell Proliferation XXIII Meeting. 15-18 October 1999. Manchester.
47. **S. Veneroni**, M.G. Daidone, E. Benini, L. Dressino. Prognostic role of p27kip1 in human breast cancer. XXVII Symposium of the Italian Cancer Society. 22-24 November 1999. Milano.
48. M.G. Daidone, C. Pellizzaro, **S. Veneroni**, L. Dressino, E. Benini. Biological characterization of matched primary and synchronous or metachronous metastatic lesions in breast cancer patients. XXVII Symposium of the Italian Cancer Society. 22-24 November 1999. Milano.
49. A. Costa, L. Licitra, **S. Veneroni**, C. Grandi, R. Erdas, M.G. Daidone. Could apoptosis-related markers give information on the outcome of primary chemotherapy in oral cavity cancer? XXVII Symposium of the Italian Cancer Society. 22-24 November 1999. Milano.
50. M.G. Daidone, E. Benini, **S. Veneroni**, R. Erdas. Expression and prognostic role of cyclin-dependent kinase (CDK) inhibitors in node-negative breast cancer (N⁻BC): p27kip1 appears to be an independent predictor. 91st Annual Meeting AACR. 1-5 April 2000. San Francisco. CA.

51. M.G. Daidone, **S. Veneroni**, E. Benini, S. Della Pasqua, D. Coradini. Expression and prognostic role of cyclin-dependent kinase inhibitors (CDK1s) in breast cancer (BC). NCI-EORTC Meeting. June 28-July 1, 2000.
52. M.G. Daidone, **S. Veneroni**, E. Benini, S. Della Pasqua, D. Coradini. Prognostic and predictive value in breast cancer (BC) of the cell cycle inhibitor protein p27kip1. 6° National Meeting S.I.C.C.A.B.. Rimini. 25-27 Settembre 2000.
53. **S. Veneroni**, E. Benini, R. Motta, S. Dellapasqua, D. Coradini, M.G. Daidone. Prognostic role of cyclin A expression in node negative breast cancer (N-BC). 6° National Meeting S.I.C.C.A.B.. Rimini. 25-27 Settembre 2000.
54. G. Pratesi, D. Laccabue, M. Tortoreto, F. Zunino, **S. Veneroni**, E. Bombardelli, M. Zucchetti, M. D'Incalci. Antitumor efficacy of i.v. Taxanes against an orthotopically implanted human glioma xenograft. 11th NCI-EORTC Symposium. 7-10 November 2000. Amsterdam.
55. M. De Cesare, G. Pratesi, **S. Veneroni**, F. Zunino. Preclinical study of antitumor effects of gimatecan (ST1481) against brain tumors. SIC 09-12 novembre 2003 Bergamo.
56. M.G. Daidone, D. Coradini, R. Erdas, G. Martelli, **S. Veneroni**. Biological features affecting breast cancer prognosis in young women. 26th Meeting of European Study Group for Cell Proliferation. 13-16 Maggio 2004. Praga (Czech Republic)
57. **S. Veneroni**, D. Coradini, E. Biganzoli, P. Boracchi, R. Erdas, L. Ventura, M.G. Daidone. Cyclin A in node-negative breast cancer: prognostic impact in the presence of conventional pathological prognostic factors. 26th Meeting of European Study Group for Cell Proliferation. 13-16 Maggio 2004. Praga (Czech Republic)
58. D. Coradini, V. Cappelletti, **S. Veneroni**, L. De Cecco, M. Gariboldi, J.F. Reid, M. Pierotti. Gene expression profiling for the prediction of response to tamoxifen in patients with breast cancer. SIC 24-27 ottobre 2004. Pisa
59. M.G. Daidone, D. Coradini, V. Cappelletti, **S. Veneroni**, M. Greco, L. Celio, E. Bajetta, J.F. Reid, L. De Cecco, L. Lusa, M. Gariboldi, M. Pierotti. Gene expression profiling and clinical outcome of breast cancer patients following neo-adjuvant or adjuvant treatment with selective estrogen receptor modulator (SERMS). American Association for Cancer research- AACR, 2005
60. M.G. Daidone, A. Carbone, **S. Veneroni**, A. Pellegrinelli, M. Fedeli, S. Toffanin, M. Gariboldi, L. De Cecco, M. Pierotti. Frozen tissue bank at Istituto Nazionale Tumori of Milan: perspectives, problems and possible solutions in real practice. Roma 19 ottobre 2006

61. **S. Veneroni**, V. Cappelletti, P. Miodini, V. Musella, L. De Cecco, M. Gariboldi, M.G. Daidone. Biobanking of frozen tissue: effect of tissue warm ischemia time on RNA degradation. ISCO congress Amsterdam March 5-8 2008
62. A. Carbone, A. Gloghini, **S. Veneroni**, M.G. Daidone, M. Pierotti. Human frozen tumor tissue bank. OEI Pathobiology workshop Cluj-Napoca Romania October 24-25 2008
63. N. Zaffaroni, Z. Sangale, **S. Veneroni**, J. Reid, M. Colecchia, A. Carlson, R. Valdagni, A. Gutin, M.G. Daidone and S. Stone. PTEN expression predicts biochemical recurrence in prostate cancer. ASCO, December 2009
64. **S. Veneroni**, M.G. Daidone, M. Milione, M. Barisella, M. Torresani, E. Sini and M. Pierotti. Human Tissue Bank facility of the Fondazione IRCCS Istituto Nazionale Tumori (INT) of Milan: the tissue issue and beyond. ESBB Conference Marsiglia November 16-19 2011
65. I. Bongarzone, M. Cremona, V.A. Espina, F. Miccichè, **S. Veneroni**, M. Colecchia, M. Pierobon, J. Deng, C. Mueller, G. Procopio, C. Lanzi, E. Petricoin III and L.A. Liotta. Signaling pathway-based stratification of clear cell renal cell carcinoma. ASCO, February 2-4 2012